Search results
Results From The WOW.Com Content Network
Pantoprazole, sold under the brand name Protonix, among others, is a medication used for the treatment of stomach ulcers, short-term treatment of erosive esophagitis due to gastroesophageal reflux disease (GERD), maintenance of healing of erosive esophagitis, and pathological hypersecretory conditions including Zollinger–Ellison syndrome.
When two drugs affect each other, it is a drug–drug interaction (DDI). The risk of a DDI increases with the number of drugs used. [1] A large share of elderly people regularly use five or more medications or supplements, with a significant risk of side-effects from drug–drug interactions. [2] Drug interactions can be of three kinds:
Omeprazole was the first PPI on the market, in 1988. It is a 1:1 racemate drug with a backbone structure of timoprazole, but substituted with two methoxy and two methyl groups. One of the methoxy group is at position 6 of the bensoimidazole and the other at position 4 of the pyridine and the methyl groups are at position 3 and 5 of the pyridine.
It is classified as a proton pump inhibitor (PPI). [1] It was approved for use in China in 2023. [ 2 ] It is formulated as its sodium salt, anaprazole sodium, in enteric-coated tablets .
1557 n/a Ensembl ENSG00000165841 n/a UniProt P33261 n/a RefSeq (mRNA) NM_000769 n/a RefSeq (protein) NP_000760 n/a Location (UCSC) Chr 10: 94.76 – 94.86 Mb n/a PubMed search n/a Wikidata View/Edit Human Cytochrome P450 2C19 (abbreviated CYP2C19) is an enzyme protein. It is a member of the CYP2C subfamily of the cytochrome P450 mixed-function oxidase system. This subfamily includes enzymes ...
You are free: to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made.
epocrates is a widely used mobile medical reference application that provides healthcare professionals with access to clinical information at the point of care. The software is designed to assist physicians, pharmacists, nurse practitioners, physician assistants and other healthcare providers in making informed decisions about drug interactions, medical calculations, diagnosis and treatment ...
[2] Proton-pump inhibitors have largely superseded the H 2-receptor antagonists, a group of medications with similar effects but a different mode of action, and heavy use of antacids. [3] A potassium-competitive acid blocker (PCAB) revaprazan was marketed in Korea as an alternative to a PPI.